- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05241340
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer (RAD-VACCINE)
A Phase II Clinical Trial of Neoadjuvant Sasanlimab and Stereotactic Body Radiation Therapy as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
Study Overview
Status
Conditions
Detailed Description
Patients with cT2-T4a, N0, M0 urothelial bladder carcinoma (UBC) after transurethral resection of the bladder will receive 2 doses of sasanlimab (PF-06801591) at the dose of 300mg subcutaneously, followed by 3 doses of radiation (8Gy x 3) prior to surgery (radical cystectomy). Cystectomy will be planned to be done within 6 weeks of the last dose of sasanlimab.
Pathologic complete response (pT0) is the primary endpoint, in addition to a safety lead-in endpoint consisting of a composite outcome of feasibility and safety.
Exploratory biomarker analysis on tissue/blood samples will include genomic and immune-system profiling in tumor and blood before and after sasanlimab/radiation therapy, and after radical cystectomy.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Maryam Anis
- Phone Number: 3462386123
- Email: manis2@houstonmethodist.org
Study Contact Backup
- Name: Taliah Muhammad
- Phone Number: 3462384523
- Email: TNMuhammad@houstonmethodist.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77006
- Recruiting
- Houston Methodist Hospital
-
Contact:
- Maryam Anis, BS
- Phone Number: 346-238-6123
- Email: manis2@houstonmethodist.org
-
Contact:
- Taliah Muhammad, BS
- Phone Number: 3462384523
- Email: tnmuhammad@houstonmethodist.org
-
Principal Investigator:
- Raj Satkunasivam, MD, MS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Capable of giving signed informed consent
- Age ≥ 18 years
- ECOG Eastern Cooperative Oncology Group performance status 0-2
- Predominant (>50%) urothelial carcinoma histology
- Muscle-invasive bladder cancer (cT2-4a, cN0, cM0)
Decline/refuse OR Ineligible to receive cisplatin-based Neoadjuvant Chemotherapy due to at least one of the following criteria:
a. Creatinine clearance less than 60 mL/min b. Eastern Cooperative Oncology Group performance status of ≥ 2 c. Grade ≥ 2 hearing loss d. Grade ≥ 2 neuropathy
Adequate Bone Marrow Function (without hematopoietic growth factor support within 14 days prior to study screening), defined as:
a. Absolute neutrophil count (ANC) ≥1,500/mm3 or ≥1.5 x 109/L b. Platelets ≥100,000/mm3 or 100 x 109/L c. Hemoglobin ≥9 g/dL (≥5.6 mmol/L)
- Adequate renal function defined by an estimated creatinine clearance ≥30 mL/min according to the Cockcroft Gault formula or by 24-hour urine collection for creatinine clearance.
Adequate liver function, including:
a. Aspartate and alanine aminotransferase (AST and ALT) ≤ 2.5 × the upper normal limit range (ULN) b. Total serum bilirubin ≤ 1.5 x ULN
- Able to give informed consent and patient is willing and able to comply with scheduled study visits and treatment plan
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other procedures.
- Meeting the following criteria for sex specific considerations:
Males - for the duration of study and for at least 6 months after the last dose of study drug (Sasanlimab):
- Refrain from donating sperm and be abstinent from intercourse OR Agree to use male condom and also consider the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant
Females:
a) Eligible to participate if not pregnant or breast feeding AND Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP and is using a contraceptive method that is highly effective (failure rate of < 1% per year), with low user dependency during the during the study treatment and for at least 6 months after the last dose of study drug (Sasanlimab) b) A WOCBP must have a negative, highly sensitive (at least 25 IU/mL) pregnancy test by urine or serum testing within 24 hours before the first dose of study drug (Sasanlimab). In cases where the urine test cannot be confirmed to be negative, a serum pregnancy test will be used.
Exclusion Criteria:
- Lymphadenopathy (>1cm short-axis measurement on CT/MRI Imaging or biopsy proven)
- Metastatic disease
- Prior systemic chemotherapy for bladder cancer (however, may have had intra-vesical chemotherapy such as gemcitabine, docetaxel or mitomycin-C)
- Prior treatment with systemic anti-cancer investigational agent
- Other malignancy within 2 years prior to study screening, or active malignancy except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix, or low-grade (Gleason 6 or below) prostate cancer on surveillance without any plans for treatment intervention (e.g., surgery, radiation, or castration) or other concurrent malignancy felt by the investigator has a very low likelihood to become metastatic
- Previous radiation therapy to the bladder
Active or history of autoimmune disease which may deteriorate when receiving immune checkpoint blockade.
- These autoimmune conditions include but are not limited to limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis
- Participants with diabetes type I, vitiligo, psoriasis, or hypo or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
- Severe active infections (e.g., pulmonary tuberculosis) requiring systemic therapeutic oral or IV antibiotics within 2 weeks prior to study entry.
- Clinically significant, multiple or severe drug allergies, intolerance to topical corticosteroids
Current unstable liver or biliary disease, defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
- NOTE: Stable chronic liver disease (including Gilbert's syndrome, asymptomatic gallstones, and chronic stable hepatitis B or C -e.g., presence of hepatitis B surface antigen [HBsAg] or positive hepatitis C antibody test result at screening) is acceptable.
- Active, uncontrolled HIV/AIDS infection (well-controlled HIV patients may be allowed).
- Prior immunotherapy with anti PD-1, anti PD-L1, anti PD-L2, or anti cytotoxic T- lymphocyte-associated antigen-4 (CTLA-4) antibody. Note: prior intra-vesical BCG therapy is acceptable.
- Prior treatment with immune-stimulatory agents including interleukin (IL)-2, IL-15, interferon (INF)- γ.
- Vaccination within 4 weeks from study screening and while on study treatment unless administration of inactivated vaccines.
- Patients with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- Clinically significant (active) cardiovascular disease including the following: cerebral vascular accident/stroke <6 months prior to screening; myocardial infarction <6 months prior to screening; unstable angina; congestive heart failure (≥New York Heart Association Classification Class III); or serious cardiac arrhythmia (uncontrolled, clinically significant) requiring medication.
- Q-T interval corrected for heart rate (QTc) >450 msec for male participants or QTc >470 msec for female participants or QTc >480 msec in participants with right bundle branch block
- Prior organ transplantation or allogenic stem cell transplantation.
- Known history of: immune-mediated colitis, inflammatory bowel disease, pneumonitis, or pulmonary fibrosis.
- Patients with intolerance to or who have had a severe (Grade ≥3) allergic or anaphylactic reaction to antibodies or infused therapeutic proteins
- Pregnant female patients; breastfeeding female patients; male patients able to father children and female patients of childbearing potential who are unwilling or unable to use a highly effective method(s) of contraception as outlined in this protocol for at least 6 months after the last dose of Sasanlimab (PF-06801591)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Open arm
All patients will receive study interventions (sasanlimab and SBRT) and standard-of-care radical cystectomy.
|
Sasanlimab (PF-06801591) is a recombinant humanized monoclonal antibody (immunoglobulin gamma-4 with kappa light chains, IgG4 kappa) directed against programmed death 1 (PD-1).
Manufactured by Pfizer, Inc.
Other Names:
This current study is designed to deliver a biologically equivalent dose of 43.2Gy using a strategy of HD hypo-fractionated radiation therapy 8Gy x 3 in combination with Sasanlimab
This will include a cysto-prostatectomy in males or a radical cystectomy with anterior exenteration in females, bilateral pelvic lymph node dissection, and creation of a urinary diversion (ileal conduit, Indiana pouch or orthotopic neo-bladder). Robotic assisted or open surgery will be permitted. Because there is currently equipoise regarding standard or extended template pelvic lymph node dissection, the limits of node dissection will not be protocol mandated. In the standard template, nodal packets will include the common iliac, external iliac, internal iliac (or hypogastric) and obturator nodes. Patients receiving an extended template will have the standard nodes with the addition of the para-aortic, para-caval, pre-sacral, and pre-sciatic node packets. The decision for urinary diversion is multifactorial involving patient factors (e.g., adequate renal function) and preference; thus, it will be made on a case-by-case basis. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite outcome for Feasibility and Safety
Time Frame: From date of registration to date of death due to any cause, assessed up to 4 weeks after radical cystectomy
|
Combination of Sasanlimab and SBRT will be deemed both feasible and safe (composite outcome) if, after the treatment of 10 patients, ≥ 7 of 10 patients meet all of the following feasibility criteria:
and meet all of the safety criteria, defined as not experiencing any following Common Terminology Criteria for Adverse Events (CTCAE) toxicities up to 4 weeks after the completion of radical cystectomy:
|
From date of registration to date of death due to any cause, assessed up to 4 weeks after radical cystectomy
|
Clinical benefit rate defined as pathologic complete response (pT0)
Time Frame: At time of radical cystectomy
|
Proportion of patients experiencing pathologic complete response (pT0) after the study treatment followed by radical cystectomy.
|
At time of radical cystectomy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events graded by NCI CTCAE version 5.0
Time Frame: From date of registration to date of death due to any cause, assessed up to 12 weeks after radical cystectomy
|
Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
|
From date of registration to date of death due to any cause, assessed up to 12 weeks after radical cystectomy
|
Incidence of major surgical complications graded by Clavien-Dindo Scale
Time Frame: From date of radical cystectomy to date of death, assessed up to 30 days following surgery
|
Clavien-Dindo scale is widely utilized for grading adverse events (i.e. complications) that may occur as a result of surgical procedures. The severity of the complication increases from grade 1 to grade 5. |
From date of radical cystectomy to date of death, assessed up to 30 days following surgery
|
Health Related Quality of Life for Patients with T2-T4 muscle invasive bladder cancer
Time Frame: From date of registration to date of death due to any cause, assessed up to 24 months after radical cystectomy
|
Patient's health related quality of life survey on 30 items including urinary symptoms, sexual function, urostomy issues, catheter use, and body image will be assessed by The European Organization for Research and Treatment of Cancer (EORTC) QOL C30-BLM 30, in order to assess changes in patient-reported quality of life at baseline and changes. Each item is scored on a 4 point scale, with a higher score reflecting a better quality of life. |
From date of registration to date of death due to any cause, assessed up to 24 months after radical cystectomy
|
Overall survival (OS)
Time Frame: From date of registration to date of death due to any cause, assessed up to 24 months after radical cystectomy
|
Overall Survival is defined as the duration of time from the date of treatment initiation that a patient is still alive.
|
From date of registration to date of death due to any cause, assessed up to 24 months after radical cystectomy
|
Recurrence free survival (RFS)
Time Frame: From date of registration to date of death due to any cause, assessed up to 24 months after radical cystectomy
|
RFS is defined as the time from surgery and study treatment to recurrence or death, whichever occurred first.
|
From date of registration to date of death due to any cause, assessed up to 24 months after radical cystectomy
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Raj Satkunasivam, MD, Houston Methodist Hospital, Houston Methodist Research Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Immunotherapy
- Urologic Diseases
- Bladder Cancer
- Neoadjuvant therapy
- Radiation
- Stereotactic Body Radiation Therapy
- Antineoplastic agents
- Immune Checkpoint Inhibitor
- Sasanlimab
- Muscle Invasive Bladder Cancer
- Urinary Bladder Diseases
- Urologic neoplasms
- Urothelial Carcinoma of the Bladder
- Antineoplastic agents, Immunological
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Urinary Bladder Neoplasms
- Carcinoma, Transitional Cell
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
Other Study ID Numbers
- PRO00032433
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urothelial Carcinoma Bladder
-
Stanford UniversityAstraZenecaTerminatedBladder Adenocarcinoma | Bladder Mixed Adenocarcinoma | Bladder Squamous Cell Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Giant Cells | Infiltrating Bladder Urothelial Carcinoma, Nested Variant | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Bladder Urothelial... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant | Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation | Infiltrating Bladder Urothelial Carcinoma With Squamous... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); National Institute for Biomedical Imaging...TerminatedStage II Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma | Bladder Papillary Urothelial Carcinoma | Stage 0a Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma | Stage I Bladder Cancer With Carcinoma In Situ | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnInfiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Stage III Bladder Urothelial CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage II Bladder Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma | Stage I Bladder Urothelial CarcinomaUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingStage 0is Bladder Urothelial Carcinoma | Stage I Bladder Urothelial Carcinoma | Stage 0 Bladder Urothelial CarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingInfiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage III Bladder Urothelial CarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial CarcinomaUnited States
-
xCuresTerminatedTransitional Cell Carcinoma | Bladder Cancer | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR2 Amplification | Bladder Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Refractory Bladder Carcinoma | Refractory Bladder Urothelial Carcinoma and other conditionsUnited States
Clinical Trials on Sasanlimab
-
PfizerRecruitingMelanoma | Neoplasms | Renal Cell Carcinoma | Non-small-cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Urothelial Carcinoma | Colorectal Carcinoma | Ovarian CarcinomaPuerto Rico, Japan, United States
-
PfizerTerminatedMelanoma | Sarcoma | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Bladder Cancer | Renal Cell Cancer | Hepatocellular Cancer | Squamous Cell Carcinoma | Non-Small-Cell Lung CancerUnited States
-
PfizerActive, not recruitingCarcinoma, Non-Small-Cell LungUnited States, Belgium, Taiwan, Australia, United Kingdom
-
National Cancer Institute (NCI)RecruitingAdvanced Clear Cell Renal Carcinoma (Ccrcc) | Papillary Renal Cell Carcinoma (Prcc)United States
-
PfizerTerminatedGastric Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Gastroesophageal Junction Cancer | Urothelial Cancer | Head and Neck Squamous Cell CarcinomasUnited States, Japan
-
PfizerWithdrawnBladder CancerPoland, United States
-
PfizerActive, not recruitingNon-muscle Invasive Bladder CancerChina, United States, Spain, Belgium, Korea, Republic of, Australia, United Kingdom, Japan, France, Germany, Canada, Russian Federation, Poland, Italy
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Seagen Inc.TerminatedCervical Cancer | Ovarian Cancer | Peripheral T-cell Lymphoma | Bladder Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Gastric Carcinoma | Classical Hodgkin Lymphoma | Diffuse Large B-cell Lymphoma | Cutaneous Melanoma | Gastroesophageal Junction...United States, Spain, Canada, United Kingdom, France, Italy
-
NiKang Therapeutics, Inc.PfizerRecruitingNeoplasms | Kidney Cancer | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Kidney Diseases | Urologic Diseases | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Recurrent... and other conditionsUnited States